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Abstract: From the current state-of-the-art, it is clear that nanotechnology applications are 
expected to bring a range of benefits to the food sector aiming at providing better quality 
and conservation. In the meantime, a growing number of studies indicate that the exposure 
to certain engineered nanomaterials (ENMs) has a potential to lead to health complications 
and that there is a need for further investigations in order to unravel the biological 
outcomes of nanofood consumption. In the current review, we summarize the existing data 
on the (potential) use of ENMs in the food industry, information on the toxicity profiles of 
the commonly applied ENMs, such as metal (oxide) nanoparticles (NPs), address the 
potential food safety implications and health hazards connected with the consumption of 
nanofood. A number of health complications connected with the human exposure to ENMs 
are discussed, demonstrating that there is a real basis for the arisen concern not only 
connected with the gut health, but also with the potency to lead to systemic toxicity.  
The toxicological nature of hazard, exposure levels and risk to consumers from 
nanotechnology-derived food are on the earliest stage of investigation and this review also 
highlights the major gaps that need further research and regulation.  
Keywords: nanotechnology; engineered nanomaterials; nanofood; metal-based nanoparticles; 
exposure; toxicity; consumer safety  
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1. Introduction 
Engineered nanomaterials (ENMs) designed for use in many commercial materials, devices and 
structures are already found in various common products—sunscreens, cosmetics, sporting goods, 
clothing, tires, electronics, etc. Nanotechnology applications also extend to techniques like drug 
delivery, diagnosis, biomedical imaging, ground water remediation, and so forth [1].  
The massive industrial production and application of ENMs currently and the predicted increase in 
the near future may result in their appearance in various environments, yielding the possibility of 
human exposure to these ENMs through inhalation, dermal contact, or ingestion. The annual release of 
ENMs into the environment cannot be accurately estimated due to the rapidly increasing production 
volumes, lack of knowledge on the amount of ENMs applied in and released from different applications 
and products. Due to high-volume production of consumer products containing ENMs, such as 
nanoparticles (NPs) of silver, titanium dioxide, zinc oxide, silica, etc. human exposure to these  
man-made NPs is possible directly (via personal healthcare products, cosmetics, food, water, drinking, 
drugs and drug delivery system) and/or indirectly, e.g., through the release of these compounds into 
the environment [2–4]. The latter may potentially result in the contamination of drinking water and 
uptake into the human food chain [5].  
The dietary consumption of NPs in developed countries is estimated more than 1012 particles/day, 
consisting mainly of TiO2 and mixed silicates [6]. In some countries, ENMs are already used in food 
supplements and food packaging, with nanoclays as diffusion barriers and Ag NPs as antimicrobial 
agents [7,8]. ENMs likely found in nanofood products fall into three main categories: inorganic, 
surface functionalized materials, and organic ENMs [7]. Inorganic nanomaterials, which will be 
mainly discussed in this review, find currently their applications in food industry (food additives,  
food packaging or storage) and include ENMs of transition metals (e.g., silver, iron, titanium, and zinc), 
alkaline earth metals (e.g., calcium and magnesium); and non-metals (e.g., selenium and silicates). 
While the successful implementation of nanotechnology is important for the growth of the global 
economy, there is also a need to consider the possible environmental health and safety impact of these 
ENMs that could lead to hazardous biological outcomes. Once in the environment, ENMs may 
undergo diverse physical, chemical, and biological transformations (e.g., deposition, adsorption, 
agglomeration, aggregation, oxidation/reduction reactions, (bio)functionalisation), potentially altering 
their biological impact and fate [5,9]. Certain local environmental factors, such as pH, salinity, microbes, 
natural organic matter, etc. may affect the reactivity, mobility, and toxicity of ENMs [10].  
An area that could highly benefit from nanotechnology is the food industry with big potentials  
for food safety, quality, and preservation (shelf life extension) [11,12]. In the food sector,  
the uses of nanotechnology-derived food ingredients, additives, supplements and contact materials  
are expected to grow rapidly. Nanotechnology analysts estimated that between 150–600 nanofoods and 
400–500 nanofood packaging applications are already on the market [13]. According to the Project on 
Emerging Nanotechnologies, as of March 2013, in the category “Food and Beverage” are indicated 
204 products, while according to potential exposure pathways into the human body from a theoretical 
perspective there are 107 products with a potency to be ingested [14]. Chaudhry et al. [7] claim that 
more than 200 companies worldwide are conducting research and development on the use of 
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nanotechnology in agriculture, engineering, processing, packaging, as well as for delivery of food and 
nutritional supplements. 
Application of ENMs in agri-food industry may pose new indirect sources of food  
contamination, as may arise from e.g., nano-sized pesticides and veterinary medicines, contact of food 
with nanoparticulate-based coatings during preparation or processing, or potential migration of ENMs 
from food packaging. There are already known examples of pesticide formulations that are based on 
microemulsion or microencapsulation technology [7]. A literature review on nenopesticides was 
published recently that combines the existing information and concludes that the nanoformulations 
expected to have significant impacts on the fate of active ingredients and/or introduce new ingredients 
for which the environmental fate is still poorly understood (e.g., Ag·NPs) [15]. Considering the lack of 
the knowledge of the environmental behaviour and the fate of ENMs, it is difficult to assess whether 
ENMs may bioaccumulate in the food chain. 
Numerous food-related applications of ENMs that have the potential to be directly or indirectly 
(e.g., after mucociliary clearance from the respiratory tract after being inhaled [16]) ingested make an 
issue of current concern the study of the potential adverse health effects of ENMs on the gastrointestinal 
tract (GIT). The whole cascade of events including absorption, distribution, metabolism and excretion/ 
elimination (ADME) that occur following ingestion determines the internal exposure and toxicity of 
ENMs. The picture becomes more complicated due to the interactions of nanomaterials with 
surrounding matrix (GI fluids, food matrix, microflora) and unexpected effects resulting from this. 
From this point of view, the interaction of NPs with food components is another aspect that may need 
consideration and about which little information is currently available. The possible interaction of food 
components may alter the physicochemical properties of ENMs that in turn may influence their 
passage through the GIT, their ADME properties. 
ENMs, due to their specific physicochemical properties and high reactivity, can influence basic 
cellular processes, such as proliferation, metabolism, and death. Individual ENMs may lead to one or 
more toxicity endpoints, resulting in dysfunction of these basic processes. In recent years,  
several in vitro studies have assessed the potential adverse health effects of ENMs, pointing out their 
ability to induce oxidative stress, release toxic ions, disrupt electron/ion cell membrane transport 
activity and cause oxidative damage and lipid peroxidation, while results from in vivo studies have 
shown that these materials can induce adverse effects on the respiratory, cardiovascular and nervous 
systems [17,18]. The most relevant pathogenetic pathway linking ENM exposure to tissue damage is 
represented by the induction of reactive oxygen species (ROS) generation [19]. The latter may 
modulate intracellular calcium concentrations, activate transcription factors, and induce cytokine 
production [20]. Other common toxicity endpoints involve cytotoxicity, genotoxicity, stimulation of an 
inflammatory and/or immune response [21].  
In this review, we will provide information on the probable sources of food contamination with ENMs, 
available toxicity profiles for the ENMs commonly applied in the food industry (metal (oxide) NPs),  
the existing data on the possible health complications on ingested NPs and the data gaps existing 
currently in this area.  
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2. Applications of ENMs in the Food Sector  
Food itself contains many nanostructured materials. This is important to note since the distinction 
between natural nanostructures and deliberately ENMs produced to a particular specification is not 
always clear. Food and feed ingredients comprise many components, including biopolymers such as 
proteins, complex carbohydrates and fats, with sizes extending down to the nanoscale (e.g., casein, 
alginic acids and micelles/foams/colloids). Natural nanostructures are not regarded as products of 
nanotechnology, and they need to be differentiated from deliberately ENMs when considering 
regulatory requirements and definitions [22]. 
A number of recent reports and reviews have identified the current and short-term projected 
applications of nanotechnologies in the food sector [23–28].  
There are already identified potential uses of nanotechnology in virtually every segment of the food 
industry (Table 1) with four key focus areas:  
(i) agriculture-pesticide, fertilizer or vaccine delivery; animal and plant pathogen detection;  
and targeted genetic engineering,  
(ii) food processing-encapsulation of flavor or odor enhancers; food textural or quality improvement; 
new gelation or viscosifying agents,  
(iii) food packaging-pathogen, gas or abuse sensors; anticounterfeiting devices, UV-protection, 
and stronger, more impermeable polymer films, 
(iv) nutrient supplements-nutraceuticals with higher stability and bioavailability.  
Table 1. (Potential) applications of nanotechnology in food science. 
Area of application Application Reference 
Agriculture 
(Nano-modification of seed  
and fertilisers/pesticides) 
Pesticides [27] 
Targeted genetic engineering [29] 
Preservation [29,30] 
Agrichemical delivery [29] 
Sensors to monitor soil conditions [31] 
Processing 
(Interactive smart food) 
Nanoencapsulation of flavors/aromas [32–37] 
Nanoemulsions [38] 
Anti-caking agents [39] 
Nutrition 
(Food fortification  
and modification) 
Nutraceuticals [40–42] 
Nutrient delivery [32,41] 
Mineral and vitamin fortification [43,44] 
Drinking water purification [45] 
Sensory characteristics of supplements [46–51] 
Products 
(Smart packaging and food tracking)
UV protection [52–54] 
Antimicrobials [55–63] 
Condition and abuse monitors [46,47,64] 
High barrier plastics [65–68] 
Security [45,69,70] 
Contaminant sensors [51,71–75] 
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As it can be seen from Table 1, the potential for food nanotechnology applications seems unlimited. 
All facets of the food industry from ingredients to packaging and food analysis methods are  
already looking into nanotech applications. These are resulting in numerous promising applications for 
improved food production, processing, packaging, and storage [32,76,77], as well as targeted nutrient 
delivery systems [78]. Bacteria identification and food quality monitoring using biosensors;  
intelligent, active, and smart food packaging systems; nanoencapsulation of bioactive food compounds 
are a few examples of emerging applications of nanotechnology for the food industry. Perhaps the 
most advanced investigations into the use of ENMs in food applications are in food contact materials 
for the benefit of maintaining (e.g., the use of silica nano sheets to enhance barrier properties,  
the inclusion of anti-microbials such as nanosilver) or monitoring (using microbial sensors) the quality 
and safety of foods [22]. 
Another major focus of current nanotechnology application in food is the processing and 
formulation of food ingredients to form nanostructures that are claimed to offer improved taste,  
texture and consistency [79], enhanced bioavailability [80] and allow mixing of “incompatible” 
ingredients in food matrix [81]. Different types of functional nanostructures can be used as building 
blocks to create novel structures and introduce new functionalities into foods, such as nanoliposomes, 
nanoemulsions, NPs and nanofibers [79,82]. 
An example of the soluble nanomaterial under development is nanosalt, enabling consumers to lower 
their salt intake, since a small amount will cover a larger area of the food surface [83].  
Nanotechnology would even be used to manufacture “smart” packaging to dramatically extend the shelf 
life of food and enable it to be transported even further [14]. Smart packaging (containing nanosensors 
and antimicrobial activators) is being developed that will be capable of detecting food spoilage and 
releasing nanoantimicrobials to extend food shelf life, enabling supermarkets to keep food for even 
greater periods before its sale. Nanosensors embedded into food products as tiny chips invisible to the 
human eye would also act as electronic barcodes [13]. 
3. Fate of ENMs Following Ingestion 
Whether it exists as nanostructured food ingredient, nanocarrier or nano-sized particles incorporated 
in food packaging, human exposure to ENMs present in food or food contact materials occurs through 
ingestion. Owing to the huge surface area of the GIT, ingestion is probably the most common way of 
intentional exposure to various NPs. There is currently not much information regarding metabolism/ 
biotransformation of ENMs upon oral administration in human model. In this relation, there are several 
concerns, such as those connected with the small sizes of ENMs that may enter the food chain 
undetected, accumulate within tissues and organs, and taken up by individual cells [81]. There is also 
concern that the introduction into food of ENMs designed to carry dietary supplements could also lead 
to introduction of foreign substances into the bloodstream [7]. One of the different complications as a 
result of nanofood ingestion is the possibility of altered absorption profile and metabolism in the body. 
The latter could occur as a result of several processes: 
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1. As ENMs have been shown to have a greater ability to cross the gut wall, as compared to 
microparticles of the same kind, their enhanced absorption and bioavailability would result in 
higher internal exposure (higher plasma concentrations). The nanofood may also alter the way by 
which food ingredients are distributed or behave in the GIT [7]. 
2. It is not only the bulk material of the ENM that may trigger biological effects. ENMs may form a 
biofunctional corona and thus act as carriers of these substances to different biological tissues, 
potentially influencing the absorption of molecules, e.g., by introducing unintended molecules 
across the GIT and lead to unpredictable effects, known as “Trojan horse” effect [83].  
3. In addition, it has been shown that the consumption of food containing NPs has the potential to 
alter body metabolism of experimental animals. For instance, oral administration of  
nanocalcium-enriched milk has been shown to alter the calcium metabolism in rats [84].  
ENMs entering the body through ingestion are subject to digestive processes in the GIT. The GIT 
and its mucosal layer should play the role of a selective barrier to systemic exposure of materials, 
including particulate matter, in which case the ENM may remain in the gut lumen, perhaps with a 
potential for interaction with GIT surfaces or with inhabitants of the lumen (e.g., microbiota),  
but essentially being fully eliminated from the body via the faeces. The behavior of ENMs entering the 
body through ingestion are described in [85] and schematically presented in Figure 1. 
Figure 1. The fate of food-related ENMs in the GIT (modified from Cockburn et al. [22]). 
 
The GIT is also covered by a protective layer of mucus, i.e., a complex network of highly branched 
glycoproteins and macromolecules. The importance of this mucosal layer as a barrier to ENMs uptake 
(and so also for consideration in any in vitro testing methodology) has been demonstrated [86,87]. 
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Absorption of particulate material occurs across the GIT (mainly in the small intestine) primarily via 
transcytosis in the M-cells of the Peyer’s Patches in the gut-associated lymphoid tissue, and has been 
described for the uptake of NPs (20–100 nm) and small microparticles (100–500 nm) [88]. 
Translocation through the gut epithelium leads to internal systemic exposure, where ENMs could be 
distributed throughout the body, gain access to other internal body compartments with further 
internalization and retention in cells and organelles. For example, an ENM may enter the bloodstream 
via portal circulation to the liver or via mesenteric lymph nodes into the lympho-reticular system, 
enabling transport throughout the body and to other organs. 
It is accepted that the physicochemical characteristics of ENMs are the key determinants of their 
techno-biological functionality, as well as the source of potential adverse health effects. A list of such 
physicochemical properties has been defined by the Organisation for Economic Co-operation and 
Development (OECD) [89]. Amongst these parameters the size, chemical composition aggregation/ 
agglomeration state, and surface treatment/coating of ENM appear to be most critical for nanotoxicity 
issues [90]. Solubility is another key physicochemical property that warrants particular consideration, 
where insoluble or only partially soluble in the digestive fluids ENMs are paid more attention due to 
their potential to cross the GIT as an intact particle. As stated by the EU Scientific Committee on 
Emerging and Newly Identified Health Risks (SCENIHR), free and low solubility ENMs are a priority 
concern for human and environmental safety [91].  
Another important issue to be considered in the assessment of hazardous effects of ENMs to human 
health and the environment is the understanding of how the ENM was manufactured. Nanoscale impurities 
may arise from the manufacturing process, where changes such as the use of different solvents, 
time/temperature conditions and changes to the starting chemicals (e.g., alternative starting materials, 
different purity levels or concentrations of chemicals) may influence the types and/or quantities of 
impurities in the final product [92]. Surfactants can drastically change the physicochemical properties of 
ENMs, such as magnetic, electric, optical properties and chemical reactivity [93–96], thus affecting 
their cytotoxicity. It was shown that NPs coating with various types and concentrations of surfactants 
before injection significantly affects their distribution in the body [96]. Surface coatings can render 
harmful particles non-toxic while less harmful ones can be made highly toxic. Hence, additional agents, 
e.g., dispersing agents and surface modifiers often used in the manufacture of ENMs should be 
considered in the safety assessment of ENMs. 
In the GIT the physicochemical properties of ENMs may change as a result of their interaction with 
food, digestive enzymes, electrolytes, intestinal microbiota, etc. [97–99]. In addition, pH varies in 
different segments of the GIT, which may change the reactivity and toxicity of the particles. When in 
biological fluids, whether these are fluids of the GIT or a culture microenvironment, ENMs will 
develop a corona of adsorbed proteins, small molecules, and ions [100–102]. The physicochemical 
properties of such an ENM-protein complex often differ significantly from those of the pristine ENM, 
which in turn reflects on the subsequent biological responses that are evoked in cells and tissues,  
and on biodistribution profiles of the ENMs in the body [101,103]. For instance, corona formation may 
lead to decreased cytotoxicity, possibly by decreasing the cellular uptake of NP [104] or mitigating cell 
membrane damage [105]. Therefore, it is generally accepted that the protein corona, rather than the 
pristine NP itself, defines the biological identity of NPs [101,106,107]. 
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It worth noting that the body also produces nanomaterials de novo in the gut lumen. For example 
calcium phosphate NPs (20–200 nm) are formed in the mid-distal aspect of the small intestine due to 
homeostatic secretion and co-precipitation of calcium and phosphate ions [108]. Van der Zande et al. [109] 
have shown the in vivo formation of Ag NPs from silver ions probably composed of silver salts.  
This possibility should also be taken into account when assessing the toxicity profiles of ENMs, 
especially in the case of materials that tend to release ions, as these ions may form NPs in the intestine 
and thus lead to unpredictable health complications.  
4. Food-associated ENMs: Metal (Oxide) NPs and Their Toxicity Profiles 
ENMs that are considered to be likely ingested may be separated into several main  
categories–metals and metal oxides, carbon-based materials (e.g., fullerenes, carbon nanotubes), 
polymeric/dendrimeric materials and liposomes. Among these categories, the metal/metal oxide NPs 
presently have the highest potential to be ingested due to their increasing inclusion in dietary 
supplements and food conservation materials [24,110,111]. Currently, metal (oxide) NPs have not 
been comprehensively assessed in regard to the potential effects on human health. Below we will 
discuss the existing information on hazard identification of mostly applied metal-based NPs on the GIT 
based on both in vitro cell-based assays and in vivo animal experimentation.  
4.1. NanoSilver  
Ag NPs are currently used in more manufacturer identified products than any other nanomaterial [112]. 
There are (as of November 2013) at least 390 products that utilize some form of nanosilver for their 
function [113]: textiles (socks and linens), cosmetics/hygiene products (toothpastes, make-ups), 
appliances (washing machines and refrigerators), cleaning agents (detergents, soaps), kitchen supplies 
(food storage containers, bakeware, cutting boards), toys and building materials (paints, caulks, glues). 
The use of Ag NPs as an antimicrobial, antiodor, and a health supplement has already surpassed all 
other ENMs currently in use in different sectors [112,113]. 
Currently very little work has been done to assess the ability of NPs in general, and Ag-NPs in 
particular, to migrate from the packaging material into the food. Emamifar et al. [114] revealed 
evidence of migration from packaging materials (orange juice package) incorporating Ag or ZnO 
antimicrobial NPs into a food substance. Ag NPs being incorporated into cellulose pads (fresh beef 
packaging) are found to lead to detectable levels of silver ions (Ag+) leeched into the meat exudates 
(though not into the meat itself) [115]. There is thus a current need to study the relationships between 
particle characteristics, polymer type, food pH/polarity and environmental conditions relevant to food 
production, storage and packaging (e.g., temperature, pressure, humidity, light exposure, storage time). 
This information will lead to a better understanding of human exposure levels and ease the assessment 
of important aspects of the safety of Ag NP-based food contact materials. 
There is growing evidence that Ag NPs are highly toxic to mammalian cells and human  
health [116,117]. Ag NPs have been shown to damage brain [118], liver [119] and the GIT [120] cells, 
have specific effects on mitochondria and induce oxidative stress [119]. Ag NPs have been shown to 
damage cells derived from human and mammalian skin, liver, lung, brain, vascular, and reproductive 
tissues when evaluated in vitro [121]. At high doses, they have been shown to compromise the blood-
Int. J. Environ. Res. Public Health 2014, 11 5728 
 
 
brain barrier and cause neurotoxicity in rats and mice [122–124], as well as the integrity of the gut 
barrier [121]. Ag NPs at low concentrations in vitro caused changes to the cell cycle progression of 
human hepatoma cells, whereas at higher concentrations induced abnormal cellular morphology,  
cell shrinkage, and chromosomal damage to a much worse extent than that caused by similar Ag+ 
concentrations, indicating that the toxicity of Ag NPs is not only caused by ion release [125].  
In the recent study aimed at unraveling the toxicity of Ag-NPs to GIT cells, it was also shown that the 
release of Ag+ is not sufficient to explain the toxic effects of Ag-NPs [120]. However, there are very 
controversial data in this relation and there is a need of more thorough investigation with consideration 
of environmental conditions, e.g., the presence of complex food matrix, temperature, etc.  
While there is a growing number of in vitro studies showing that Ag NPs are cytotoxic to a variety 
of mammalian cell types, in vivo studies that have investigated the systemic effects of Ag NPs upon 
exposure by oral route are more ambiguous. For example, though Ag NPs were found distributed in 
virtually every organ of rats fed a steady NP diet, there were few toxic effects observed except at the 
highest concentrations [126,127]. An oral intake study in weaning pigs showed Ag NP accumulation in 
the liver with no acute toxic effects revealed [128]. In addition, lymphocyte infiltration and inflammation 
has been observed in the livers of mice fed nano- and micro-sized Ag particles, an effect that was 
exacerbated when particle diameter was on the nanoscale [129]. Van der Zande et al. [107] have 
revealed that Ag NPs were present in practically all organs with the highest levels in the liver and 
spleen. Silver concentrations in the organs were highly correlated to the amount of Ag+ in the Ag NPs 
suspension, indicating that mainly Ag+, and to a much lesser extent Ag NPs, passed the intestines in 
the Ag NP exposed rats. The authors also demonstrated a long retention of silver in brain and testis, 
which should be further considered in a risk assessment of these NPs. 
Given the still small number of in vivo toxicological studies for Ag NPs, a limited generalized 
conclusion on the effects of Ag NP exposure via food-relevant routes could be done. It is, for example,  
still unclear: (i) to what extent the biochemical pathways facilitating the processing of Ag+ apply to Ag 
NPs; (ii) to what extent NPs pass through the intestinal lining intact or as dissolved Ag+ due to the 
highly acidic environment of the stomach; and (iii) to what extent Ag NPs can pass through natural 
biological barriers such as the gut epithelium, blood-brain barrier, the placenta or get into the breast milk. 
There is also a knowledge gap concerning the relationship between NP characteristics (size, shape, 
charge, coating, etc.) and toxicity. 
4.2. NanoTitanium 
TiO2 is in the top five of NPs used in consumer products [130], accounting for 70% of the total 
production volume of pigments [131] and consumed annually at about 4 million tons worldwide [132]. 
TiO2 can be used in paints, coatings, plastics, papers, inks, medicines, sunscreens, pharmaceuticals, 
cosmetics, toothpaste, nutritional supplements and food products, e.g., colorants [39,133–138].  
These NPs has been the subject of recent efforts to develop effective carriers that enhance the oral uptake 
of drugs and vaccines [139]. Smaller TiO2 particles have higher UV-blocking properties, which can be 
advantageous for food storage [140], as well as nanosized TiO2 prevents microbial growth [141].  
TiO2-coated packaging film has been shown to considerably reduce E. coli contamination of food 
surfaces [142] and has also been shown to disinfect water from fecal coliform [143]. A recent study 
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found that candies, sweets and chewing gums contained the highest amount of TiO2 in the scale  
of <100 nm [144]. TiO2 in anatase (E171) is commonly added to granular and powdered foods  
as anti- caking agents [145].  
There is no evidence of Ti being an essential element for human beings or animals. The Ti compound 
concentration in drinking water is generally low. A typical diet may contribute 300–400 μg/day [146]. 
TiO2 particles are produced and used in varying particle size fractions including fine (approximately 
0.1–2.5 μm) and nanosize (<0.1 μm, primary particles) [147]. Human exposure to TiO2 NPs may occur 
during both manufacturing and use. The U.S. Food and Drug Administration (FDA) approved TiO2 as 
a food color additive with the stipulation that the additive should not to exceed 1% w/w. TiO2 was also 
approved by the US FDA in food packaging [148]. In the “Risk Assessment of Manufactured 
Nanomaterials TiO2 Executive Summary” compiled by the New Energy and Industrial Technology 
Development Organization (NEDO) in Japan, the acceptable exposure concentration of TiO2 NPs was 
estimated to be 1.2 mg/m3 for an 8 h workday and a 40 h workweek [149].  
The various fields of TiO2 application makes favorable the oral exposure to these NPs.  
Wang et al. [134] investigated the distribution and acute toxicity of TiO2 nano- (25 and 80 nm) and 
microparticles (155 nm) in mice, following oral exposure (5 g/kg). According to the Scientific 
Committee on Consumer Safety (SCCS) Opinion from 22 July 2013 on nanotitanium revised on 22 
April 2014, the TiO2 NPs (anatase/rutile mixtures) showed LD50 in rat >2150 mg/kg leading to low 
acute oral toxicity [150]. TiO2 NPs have been shown to be absorbed from the GIT into the blood and 
distributed to the liver, spleen, lungs and kidneys [134]. These NPs are highly stable and thus not 
degraded in the intestine. They are, therefore, typically taken up by M-cells of Peyer’s patches and 
passed to underlying macrophages. As macrophages are also unable to digest the particles, it is 
common to see pigmentation in cells at the base of human intestinal lymphoid aggregates due to 
particle accumulation [151]. 
TiO2 NPs have been linked with potentially adverse health effects in some studies. For instance, it was 
found that mice fed certain kinds of TiO2 with their drinking water for 5 days exhibited DNA and 
chromosomal damage and inflammation [136]. Studies on TiO2 NPs have shown that it destabilizes the 
cell membranes of digestive gland tubes ex vivo [152]. Recently, a review discussed very well the  
in vitro and in vivo toxicity effects of TiO2 [146]. From the available so far data, it is clear that TiO2 
NPs can be absorbed through the lung or GIT into systemic circulation and then distributed in different 
organs such as liver, kidneys, spleen, or even brain causing localized effects. However, the rate of such 
translocation is currently uncertain. TiO2 NPs may have the potential to penetrate the blood-brain, 
blood-testis and blood-placenta barriers. However, the rate of translocation appears low and evidence 
is lacking that could link systemic responses to translocation of particles to target sites.  
Many studies have been conducted in vitro and in vivo to investigate the genotoxicity of TiO2 NPs, 
but the results are conflicting and doses employed were high. Certain reproductive and developmental 
toxicities in experimental animals or cell cultures have been observed in a few in vivo and in vitro 
studies. Whether human exposure to TiO2 NPs causes reproductive and developmental toxicities is 
unclear. In addition, TiO2 NPs induced oxidative stress and alterations in cell signal transduction 
pathways that may play an important role in the etiology of TiO2 NP-induced carcinogenesis of TiO2 at 
relatively high doses. However, these studies should be repeated at doses relevant to normal 
occupational or environmental exposure conditions. Therefore, further investigations are needed to 
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elucidate the molecular mechanisms of toxicity of TiO2 NPs, as well as their systemic toxicity when 
exposed to real-world doses both acute and chronic. 
 
4.3. NanoZinc 
ZnO is another commonly used particle with similar utility to TiO2. ZnO NPs are widely used in 
various applications including cosmetics, paints, as drug carriers and fillings in medical materials [153]. 
ZnO exhibits antibacterial activity that increases with decreasing particle size [154], which could be 
stimulated by visible light [155]. ZnO NPs have been incorporated in a number of different polymers 
including polypropylene [156]. In addition, ZnO effectively absorbs UV light without re-emitting it as 
heat and therefore improves the stability of polymer composites. ZnO is also used in nutritional 
supplements such as multivitamins [43,44]. 
Exposure of RKO and Caco-2 human colon carcinoma cells to ZnO NPs (8–10 nm) revealed 
changes in metal metabolism, chaperonin proteins, and protein folding genes after gene profiling, 
without a pro-inflammatory effect [157]. Cytotoxicity of the same ZnO NPs to RKO human colon 
carcinoma cells was dependent on direct particle-cell contact and independent of the Zn2+ concentration 
in cell culture medium [158]. Exposure of the LoVo human colon carcinoma cell line to 50–70 nm 
ZnO NPs resulted in decreased viability, oxidative stress, depolarization of the inner mitochondrial 
membrane, apoptosis, and IL-8 release [159]. Another recent study also demonstrated time- and  
dose-dependent cytotoxicity of ZnO NPs on Caco-2 cells after 24 h exposure [160]. Here the authors 
also revealed that ZnO NPs exert different size-dependent cytotoxic effects with the highest toxicity to 
Caco-2 cells at 26 nm. These ZnO NPs at 26 nm could also reduce the G1 phase, increase the S phase 
and the G2 phase cells to repair damaged genes, while no differences were obtained between 62 nm 
and 90 nm ZnO NPs [160]. 
In vivo studies on mice have shown that the Zn concentration in the liver, spleen and kidney was 
higher after administration of zinc in nano form compared to similar amounts of ZnO microparticles. 
Oral NP administration resulted in transient histopathology of the liver that was not seen after 
administration of micro-sized ZnO particles [54]. The oral toxicity of ZnO NPs in mice revealed that 
NPs cause lung, liver and kidney damages [161]. Recorded significant increases in alanine and 
aspartate aminotransferases activity in all mice exposed to ZnO NPs suggest that these NPs can cause 
hepatic injury. These results were confirmed in another study [162]. Oral administration of 100 nm 
ZnO NPs (2.5 g/kg of body weight) resulted in their accumulation in the liver, spleen, lung, and 
kidney. In contrast to intraperitoneal administration, ZnO NPs did not accumulate in the heart [161]. 
More information on the existing literature on mammalian toxicity of ZnO NPs, both in vitro and in 
vivo, is nicely summarized in a recent review [163]. 
4.4. NanoSilica 
Mesoporous SiO2 NPs have been extensively explored as effective drug delivery systems for a wide 
variety of therapeutic agents to fight against various kinds of diseases, e.g., tissue engineering, 
diabetes, inflammation and cancer [164–167]. Food-grade silica has traditionally been synthetic 
amorphous SiO2 produced in a variety of forms (pyrogenic, gel, sol, precipitate). Amorphous SiO2 has 
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been used for many years in food applications, such as for clearing beers and wines, as anticaking 
agent to maintain flow properties in powder products and to thicken pastes [110], and as a carrier  
for fragrances or flavors in food and nanofood products [168,169]. The conventional form of SiO2  
is known as the food additive E551. Dekkers et al. [111] estimated that the food products including 
E551 contain nanosilica ranged from <0.1–6.9 mg/g product based on the total silica concentration, 
where the particles sizes were ranging from 30–200 nm. The authors estimated that intake of  
SiO2 NPs based on consumption of food products analyzed for their nanosilica or silica concentration  
is about 124 mg/day.  
The abovementioned data, as well as growing biomedical and pharmacological applications of SiO2 
NPs make an issue of current importance to investigate the influence of these NPs on the biological 
systems and on the GIT in particular. The in vitro cytotoxicity effects showed that SiO2 NPs  
(25 and 100 nm) induced a rather limited cytotoxic and genotoxic effects on HT-29 cells after 24 h 
exposure, with more expressed toxicity at lower concentrations [170]. From this study it could be 
concluded that SiO2 at 100 nm is more cytotoxic and genotoxic than SiO2 at 25 nm, but with an inverse 
relationship between effects and dose. The uptake following ingestion of SiO2 NPs cannot be excluded 
also given the reported oral toxicity data [110,168,171]. Particularly, it was shown that 10 weeks fed 
mice with amorphous SiO2 (30 nm, 140 g/kg mice) showed higher value of alanine aminotransferase 
activity than normal and micron-sized silica dieted groups [172]. Recently, it was concluded that single 
SiO2 NPs may be more easily absorbed from the human intestine [173], but that no conclusion on the 
oral bioavailability of synthetic amorphous silica or nano-sized silica can be drawn so far. 
5. Health Implications of Nanofood, Consumer Safety Issues and Regulatory Aspects 
Much of the debate about the safe use of nanotechnology in the food sector has focused on the 
uncertainties and the lack of toxicological data. At present, there is no tenable evidence and no general 
conclusion can be made on whether the food or food contact materials derived from nanotechnology 
are either safer or more dangerous than their conventional counterparts. Most scientific committees 
that have reviewed the applications of nanotechnology concluded that while consumers are likely to 
benefit from this technology, new data and new measurement approaches may be needed to ensure that 
the safety of products using nanotechnology are properly assessed [22, 76,174,175]. The approaches 
for safety evaluation of ENMs vary from country to country but presumably follow similar pathways 
to those used for other materials proposed for use in food and food contact materials [176]. 
The information on the ENMs influence on the GIT is scarce. Recently, it was suggested that there 
could be an association between high levels of dietary NPs uptake and Crohn’s disease.  
Experimental results indicate that the accumulation of insoluble NPs in humans may be responsible for 
the compromised GI functioning, as described in the case of Crohn’s disease and ulcerative colitis [39]. 
Thus, an issue to be considered in relation to ENMs ingestion is the possible increase in their intestinal 
absorption in the case of systemic exposures, such as in Inflammatory Bowel Disease (IBD)—a 
chronic disorders characterized by recurrent and serious inflammation of the GIT [177].  
In addition, the exposure to some NPs is associated with the occurrence of autoimmune diseases,  
such as systemic lupus erythematosus, scleroderma, and rheumatoid arthritis [6]. Moreover, nano- and 
microsized particles have been found to induce granulomas in different organs and tissues:  
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inorganic particles heterogeneous in nature but homogeneous in size have been identified in liver and 
kidney biopsies from patients with granulomatosis of unknown origin (10–20 μm and 6–8 μm in the 
liver and kidney, respectively) [178]. Micro- and nanoparticles of non-biodegradable inorganic 
exogenous pollutants have been found in colon tissues affected by cancer and Crohn’s disease [179]. 
Concomitantly, both TiO2 (anatase) and aluminosilicate (as kaolinite) are commonly seen in the human 
intestinal lymphoid aggregates [180,181]. 
The exposure to ENMs may potentially lead to an immunomodulatory effect. Recent data indicate 
that systemic exposure to a single administration of ZnO NPs could enhance subsequent antigen-specific 
immune reactions, including the serum production of antigen-specific antibodies, and the functionality 
of T cells [182]. The immune effects of nano-TiO2 exposure were shown to be route-of-exposure 
dependent. After 28 days of oral gavage of mice with TiO2 NPs, irritancy and/or potential hypersensitivity 
responses were shown [183]. Exogenous NPs were found in macrophages accumulated in lymphoid 
tissue of the human gut, the lymphoid aggregates [39]. Microscopy studies showed that macrophages 
located in lymphoid tissue uptake NPs, such as spherical anatase (TiO2) with size of 100–200 nm from 
food additives, aluminosilicates in the 100–400 nm range, typical of natural clay, and environmental 
silicates of 100–700 nm with various morphologies [180]. All these data indicate that ingested ENMs 
have a potential to cause inflammatory response, lead to impaired mucosal immunity and thus to 
inflammation-associated diseases, e.g., Crohn’s disease and ulcerative colitis [39] or to induce allergic 
sensitization and result in allergic diseases, such as food allergy. 
Recently, the results of studies conducted to assess the potential toxic effects of ENMs have 
suggested a number of adverse effects on human health such as alterations in the development and 
growth process, leading to the disruption of the endocrine system. The adverse effects of ENMs on the 
endocrine system are still unclear and unexplored and the potency of ENMs as endocrine disruptors 
should be taken into account. A recent review [184] summarizes and discusses recent reports derived 
from cell lines or animal models concerning the effects of ENMs on, and their application in the 
endocrine system of mammalian and other species. It presents an update on current studies of the 
effects of some typical NMs, e.g., metal- and carbon-based NMs, and dendrimers on endocrine 
functions, in which some effects are adverse or unwanted and others are favorable or intended.  
Studies of the reproductive function suggest that exposure to some ENMs may disrupt endocrine 
functions such as regulation of serum sex hormone levels. In contrast, other NMs may prevent 
endocrine dysfunction via various mechanisms, including antioxidant effects. Some recent studies 
presented evidence that metal-based ENMs, e.g., Ag, Au, Mn or Ti NPs, widely used in the consumer 
market, may exert endocrine-associated toxicity [183]. 
Another review [185] suggests that some of the ENMs may pose risks to male and female 
reproductive health by altering normal testis and ovarian structure, spermatogenesis and sperm quality, 
oogenesis, follicle maturation and sex hormone levels. Authors conclude that in the male reproductive 
system NPs are able to affect cell viability in gonadal tissues, testicular morphology and the process of 
spermatogenesis, whereas in the female reproductive system, NPs exert cytotoxic and/or genotoxic 
effects on ovarian structural cells and damage oogenesis and follicle maturation. Furthermore, NPs were 
able to cause significant alterations in normal sex hormone levels in both systems [185].  
However, some studies failed to confirm these adverse effects, since no abnormalities in male and 
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female reproductive function were found after NP exposure. These conflicting results are probably due 
to the different intrinsic properties of NPs used in the in vitro and in vivo studies. 
From the available information so far it could be concluded that further investigations are required 
to obtain a thorough understanding of any potential risk to the GIT, as well as on systemic toxicity and 
pathological endocrine disruption in particular from products containing ENMs. Systematic biosafety 
assessment is necessary to evaluate the potential endocrine-disrupting risks of ENMs, which in turn is 
associated with adverse health outcomes including reproductive failure, metabolic syndrome,  
and some types of cancer. 
Research on ingestion of ENMs as a direct exposure route is just beginning. The Food and Agriculture 
Organization and the World Health Organization [83] summarized information on the potential food 
safety implications of ENMs. According to this report, the assessment of exposures to ENMs poses 
challenges because of the need to characterize and quantify the material once it is released and to 
assess its stability and potential biotransformation during food processing or in food [83]. The crucial 
issues concern the propensity of ENMs to survive in the GIT (e.g., the acidic gastric environment),  
the ability and extent to be absorbed and assimilated in the organism.  
Another critical research question concerns the nature and implications of biomolecular 
modifications of ENMs in biological fluids and matrices. In particular, recent evidence indicates the 
formation of a “hard” corona with stable proteins and an outer, “weaker” corona that has quickly 
exchanging proteins depending on the environment [102,186]. Possible sources of surface coating/ 
contamination of NPs are diverse. One example surface contaminant is ubiquitous bacterial endotoxins 
lipopolysaccharides (LPS)-one of the most common surface-adsorbed contaminants of serious concern 
for all biomaterials [187]. In pharmaceutical industries, it is possible to find endotoxins during 
production processes or in the final product [188]. It was shown that TiO2, ZnO and SiO2, upon their 
absorption and passage across the GIT adsorb calcium ions and LPS and the resulting NPs-calcium-LPS 
conjugates activate both peripheral blood mononuclear cells and intestinal phagocytes, which are 
usually resistant to stimulation [150]. Hence, endotoxin contamination is possible on a variety of NPs, 
producing an inflammatory response that is magnified by the NPs presence to levels that would 
warrant concern over endotoxin’s potent inflammatory reactivity in vivo and with many cell lines [189]. 
Another problem arising from the use of metals in food contact surfaces depends on the quantity of 
ions able to migrate into the food matrix. An intentional migration of the active element in the food 
matrix falls under Framework Regulation for active packaging materials [190]. When ENMs come in 
contact with food, indirect contamination can also be expected, if those NMs migrate. Guidance on the 
risk assessment of ENMs has been provided by the European Food Safety Authority (EFSA) on the 
potential risks arising from nanotechnologies [191]. In cases, where ENMs are not persistent,  
may migrate, be transformed before or during ingestion, in vitro and in vivo toxicity studies are 
recommended. The importance of the legislation concerning the use of metal-based ENMs is supported 
by recent observations. For instance, the quantification of the migration of Ag NPs and Ag+ in consumer 
products revealed that both Ag+ and NPs migrate at levels that approximate the expected toxicity in some 
goods [192]. EU safety regulations indicate that Ag zeolites in food contact applications should not be 
used to extend shelf-life, and the presence of Ag+ in food matrices is limited to 50 µg Ag+/kg food, 
which is not biocide in food [193]. The US FDA approved the use of Ag as an antimicrobial in bottled 
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water, with a concentration up to 17 µg Ag+/kg [194]. The use of TiO2 as a colour additive approved 
by code E171 under is less restrictive and could be used in “quantum satis” [195]. 
Steps for the safety assessment for ENMs in foods are basically the same as those for conventional 
foods and follow the general risk assessment model [196,197]. As ENMs may be considered as 
“novel” forms of their bulk counterpart, it is insightful to consider the assessment processes developed 
for novel foods, as defined in Europe by Regulation (EC) No. 258/97 [198]. Currently in the process of 
the safety evaluation of novel foods, a comparative approach is used that makes use of existing data on 
a relevant non-novel comparator [199,200].  
In the presence of a food matrix, in addition to the characterization and safety assessment of the 
ENMs as manufactured, it is important to characterize and achieve understanding of the form of the 
ENM, whether it is free or agglomerated, soluble or insoluble, coated or pristine, formulated or 
unformulated, etc. The latter is important, as in particular, the physicochemical characteristics of other 
ingredients/components within the food may influence the degree to which the ENM is digested or 
translocated in the GIT. Additionally, ENMs may be elaborated into a range of other structures that 
may either remain intact or act as delivery systems for the ENMs. Thus it could be concluded that the 
physicochemical characterization of the ENM as manufactured, in food matrices as consumed,  
and after exposure to biological matrices such as GIT fluid, mucus, plasma, lymph, therefore plays a 
pivotal role in guiding the safety assessment program. An adequate characterization of the ENMs 
under evaluation should be conducted at an early stage. 
6. Discussion and Conclusions 
Nanotechnology is a fast-growing field of activity that will allow development of materials with 
brand-new properties. In fact, as more and more consumer products containing ENMs become 
available on the market, the exposure of the general population will inevitably increase heightening the 
concern about the potential human toxicity and environmental impact of these particles.  
However, since there is still a lack of knowledge about the possible risks to human health and 
environmental safety posed by the expanding development and use of ENMs, there seems to be an 
urgent need to gather information on this subject. In this context, we have summarized the data 
currently available in the literature that report the adverse health effects of ENMs (mainly the metal 
(oxide) NPs) upon in vitro and in vivo exposure. Our aim was to understand the risk of food-associated 
ENMs that are ingested directly or indirectly via oral route, assess the underlying mechanisms that can 
affect the GIT function and identify research areas where further study needs to be carried out to reach 
a deeper understanding of the role of ENMs in food industry and potential consumer safety issues.  
The available data indicate that some insoluble ENMs can pass through the different protective 
barriers and the GIT barrier in particular, be distributed in the body, and accumulate in several organs. 
Toxic effects have already been documented at the pulmonary, cardiac, reproductive, renal, cutaneous, 
and cellular levels, while ENMs can be distributed throughout the body, including the interior of cells. 
Significant accumulations have been shown in the lungs, brain, liver, spleen, and bones. There are still 
big gaps in the understanding to what extent one or another type of ENM passes through the intestinal 
lining intact or is dissolved in the highly acidic environment of the stomach, and to what extent these 
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ENMs can pass through natural biological barriers such as the gut epithelium, blood-brain barrier,  
the placenta or into breast milk.  
The hazard identification studies so far were conducted only on physiologically normal conditions, 
however, some diseased model conditions should be taken into account. For instance, it was revealed 
that diseases, such as diabetes, may lead to an increased absorption of particles in the GIT [201].  
Thus more vulnerable members of the population, i.e., those with pre-existing digestive disorders,  
may potentially be more affected by the presence of ENMs, although, in contrast, ENMs may offer 
many potential routes to therapies for the same diseases. In addition, the presence of inflammation may 
enhance the translocation of ENMs into circulation [202–203]. 
Computational models should play a complementary role in allowing rapid prediction of  
potential toxicities of new and modified ENMs. These in silico methods, aiming at predicting the 
toxicity of ENMs, such as Quantitative Structure Activity Relationships (QSAR) are being 
investigated and could eventually provide a useful screening tool [204–207]. QSARs are theoretical 
models that relate the structure or physicochemical properties of substances to their biological 
activities. QSARs are being applied in many disciplines, for example in risk assessment, and toxicity 
prediction [208], as well as in drug discovery and lead optimization [209], but they have yet few 
applications for NPs (nano-QSAR) [210]. Recently nano-QSAR was applied to predict the cytotoxicity 
of metal oxide NPs [211], as well as predictive models of cellular uptake and apoptosis induced  
by NPs for several cell types was developed by Epa et al. [212]. The reliable QSAR models thus  
may provide a tool to predict the toxicity of ENMs, understand the link between the ENMs 
physicochemistry and the toxicity endpoints, as well as design safe nanomaterials for future 
biomedical and food applications. 
Since the biological and toxic effects of ENMs are highly dependent on their physicochemical 
properties (size, shape, charge, coating, solubility etc.) as well as on dosage, route of administration, 
duration of exposure, etc. it becomes evident that a clear and precise evaluation of the biological  
effects of ENMs should also include a homogeneous exposure classification to ascertain exactly how 
the physicochemical properties of ENMs correlate with their adverse health effects.  
Useful parameters for a systematic categorization should include e.g., chemical composition, 
morphology, number concentration, surface area, mass concentration, weighted size distribution,  
state of agglomeration and surface reactivity (ability to produce radicals, zeta potential, etc.),  
as well as the surface (bio)functionalization when in contact with the surrounding matrix or biological 
media. This is fundamental for the assessment of the toxicity profiles of ENMs. Unfortunately much of 
this characterization is largely lacking in current studies due to the complicate nature of the 
characterization process (especially in biological fluids and food matrix). Better understanding of the 
processes underlying the interaction of ENMs with biomolecules will serve as a basis for biological 
and medical applications of ENMs. 
Conducted toxicity studies aimed at identifying the potential risks of ENMs using various in vitro or 
in vivo assays frequently applied excessive and unrealistically high mass doses of ENMs and it is 
debatable whether the findings observed in these studies can be extrapolated to refer to humans in real 
life. It is therefore arises a need to study more realistic lower exposure scenarios both acute and 
chronic to have better relevance to the real-world conditions. Given the poor availability data on 
exposure levels of general population to food-associated ENMs, it is not easy to determine a realistic 
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exposure dose to be used in the toxicological studies. In addition, the impact of traditional heat 
treatment against complement or other treatments (e.g., sonification) must all be addressed as 
important controls, if the results are to be meaningful for extrapolation to the in vivo, real consumer 
situation [213]. However, it seems clear that further studies need to focus on the potentially adverse 
effects of low-level ENM exposure with more emphasis on the matrix, where the ENMs actually are. 
Moreover, to immediate effects, time-series studies have shown cumulative effects over weeks, 
associated with elevated particle concentrations [214]. Hence, further studies are necessary to assess 
the health effects of chronic exposure to ENMs. 
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